Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker
- 1 July 2009
- journal article
- clinical trial
- Published by Elsevier BV in Genetics in Medicine
- Vol. 11 (7), 536-541
- https://doi.org/10.1097/gim.0b013e3181a87867
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- CORRECTIONNeurology, 2008
- Long-Term Enzyme Replacement Therapy for Pompe Disease With Recombinant Human Alpha-glucosidase Derived From Chinese Hamster Ovary CellsJournal of Child Neurology, 2007
- Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe diseaseLaboratory Investigation, 2006
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006
- Pompe disease diagnosis and management guidelineGenetics in Medicine, 2006
- Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trialNeuromuscular Disorders, 2005
- Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human α-Glucosidase From MilkPEDIATRICS, 2004
- Enzyme therapy for Pompe disease with recombinant human α‐glucosidase from rabbit milkJournal of Inherited Metabolic Disease, 2001
- Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trialGenetics in Medicine, 2001
- Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogenClinica Chimica Acta; International Journal of Clinical Chemistry, 1988